Bone tumors effective therapy through functionalized hydrogels: current developments and future expectations.

Primary bone tumors especially, sarcomas affect adolescents the most because it originates from osteoblasts cells responsible for bone growth. Chemotherapy, surgery, and radiation therapy are the most often used clinical treatments. Regrettably, surgical resection frequently fails to entirely eradicate the tumor, which is the primary cause of metastasis and postoperative recurrence, leading to a high death rate. Additionally, bone tumors frequently penetrate significant regions of bone, rendering them incapable of self-repair, and impairing patients' quality of life. As a result, treating bone tumors and regenerating bone in the clinic is difficult. In recent decades, numerous sorts of alternative therapy approaches have been investigated due to a lack of approved treatments. Among the novel therapeutic approaches, hydrogel-based anticancer therapy has cleared the way for the development of new targeted techniques for treating bone cancer and bone regeneration. They include strategies such as co-delivery of several drug payloads, enhancing their biodistribution and transport capabilities, normalizing accumulation, and optimizing drug release profiles to decrease the limitations of current therapy. This review discusses current advances in functionalized hydrogels to develop a new technique for treating bone tumors by reducing postoperative tumor recurrence and promoting tissue repair.

State of the art of bone biomaterials and their interactions with stem cells: Current state and future directions.

BACKGROUND: There has been a rapid increase in bone tissue regeneration since the concept of "tissue engineering." Stem cell-based biomaterials have revolutionized the field of tissue regeneration. Biomaterials play an essential part in bone regeneration through their crucial substratum for cell differentiation, cohesion, and proliferation by manipulating cells. Numerous studies have been carried out in order to create a biomaterial with diverse biological and physical characteristics. Furthermore, they developed a cell microenvironment with the desired pore magnitude to stimulate stem cells to transform them from artificial to biological microenvironments. PURPOSE AND SCOPE: The current review aims to give a comprehensive overview of stem cells and biomaterials in bone tissue regeneration. SUMMARY: Initially, bone biology and its interaction with stem cells and biomaterials are briefly explained. Following that, the behavior and mechanism of biomaterials influencing the stem cells during bone tissue regeneration are emphasized. Lastly, the future outlook for tackling the current challenges for designing biomaterials/stem cell materials for bone tissue engineering (TE) is discussed. CONCLUSION: Compatible biomaterial for bone regeneration requires evaluating the structure, matrix, composition, flexibility, and nature of native bone tissue defects. The concept of TE offers a platform for designing biologically, physically, and chemically biocompatible biomaterials for stem cells to proliferate and differentiate. Currently, stem cells are increasingly used for TE with a promising outcome due to their self-renewal and differentiation potential. Furthermore, they can secrete biological-active compounds and modulate the fate and behavior of other cells in native tissues. Bone TE may flourish more rapidly and efficiently using stem cells.

Application of nanoparticles in drug delivery for the treatment of osteosarcoma: focussing on the liposomes.

Osteosarcoma (OS) is one of the most common primary bone malignancies in children and adolescents. The toxicity to healthy tissues from conventional therapeutic strategies, including chemotherapy and radiotherapy, and drug resistance, severely affects OS patients' quality of life and cancer-specific outcomes. Many efforts have been made to develop various nanomaterial-based drug delivery systems with specific properties to overcome these limitations. Among the developed nanocarriers, liposomes are the most successful and promising candidates for providing targeted tumour therapy and enhancing the safety and therapeutic effect of encapsulated agents. Liposomes have low immunogenicity, high biocompatibility, prolonged half-life, active group protection, cell-like membrane structure, safety and effectiveness. This review will discuss various nanomaterial-based carriers in cancer therapy and then the characteristics and design of liposomes with a particular focus on the targeting feature. We will also summarise the recent advances in the liposomal drug delivery system for OS treatment in preclinical and clinical studies.

In vivo behavior of bioactive glass-based composites in animal models for bone regeneration.

This review presents the recent advances and the current state-of-the-art of bioactive glass-based composite biomaterials intended for bone regeneration. Composite materials comprise two (or more) constituents at the nanometre scale, in which typically, one constituent is organic and functions as the matrix phase and the other constituent is inorganic and behaves as the reinforcing phase. Such materials, thereby, more closely resemble natural bio-nanocomposites such as bone. Various glass compositions in combination with a wide range of natural and synthetic polymers have been evaluated in vivo under experimental conditions ranging from unloaded critical-sized defects to mechanically-loaded, weight-bearing sites with highly favourable outcomes. Additional possibilities include controlled release of anti-osteoporotic drugs, ions, antibiotics, pro-angiogenic substances and pro-osteogenic substances. Histological and morphological evaluations suggest the formation of new, highly vascularised bone that displays signs of remodelling over time. With the possibility to tailor the mechanical and chemical properties through careful selection of individual components, as well as the overall geometry (from mesoporous particles and micro-/nanospheres to 3D scaffolds and coatings) through innovative manufacturing processes, such biomaterials present exciting new avenues for bone repair and regeneration.

Long non-coding XIST raises methylation of TIMP-3 promoter to regulate collagen degradation in osteoarthritic chondrocytes after tibial plateau fracture.

BACKGROUND: Hypermethylation of gene promoters has been regarded as an epigenetic regulator for gene inactivation in the development of several diseases. In the current study, we aimed to explore how long noncoding RNA X-inactive specific transcript (lncRNA XIST) function in collagen degradation in chondrocytes of osteoarthritis (OA) after tibial plateau fracture by regulating tissue inhibitor of metalloproteinase-3 (TIMP-3) promoter methylation. METHODS: In silico analysis was used to screen differentially expressed lncRNAs in cartilage tissues of OA. Chondrocytes were then successfully isolated from normal and OA cartilage tissues and identified, with the expressions of lncRNA XIST and TIMP-3 examined. The methylation levels of TIMP-3 promoter were determined by MS-PCR. The binding of lncRNA XIST to DNA methyltransferase and the binding of TIMP-3 promoter to DNA methyltransferase were determined by a series of experiments, including RIP, RNA pull-down, and ChIP assays. RESULTS: The differentially expressed lncRNA XIST was determined in OA. In addition, cartilage tissues of OA showed upregulation of lncRNA XIST and downregulation of TIMP-3. LncRNA XIST was primarily localized in the nucleus and was capable of binding to the promoter of TIMP-3. The silencing of lncRNA XIST decreased the methylation levels of TIMP-3 promoter and increased the expressions of TIMP-3, which consequently inhibited collagen degradation in OA chondrocytes. Furthermore, TIMP-3 over-expression reversed the effect of lncRNA XIST on collagen degradation in OA chondrocytes. CONCLUSION: Collectively, lncRNA XIST raises collagen degradation in OA chondrocytes after tibial plateau fracture by accelerating the methylation of TIMP-3 promoter by recruiting DNA methyltransferase.

Industrial demonstration plant for the gasification of herb residue by fluidized bed two-stage process.

A fluidized bed two-stage gasification process, consisting of a fluidized-bed (FB) pyrolyzer and a transport fluidized bed (TFB) gasifier, has been proposed to gasify biomass for fuel gas production with low tar content. On the basis of our previous fundamental study, an autothermal two-stage gasifier has been designed and built for gasify a kind of Chinese herb residue with a treating capacity of 600 kg/h. The testing data in the operational stable stage of the industrial demonstration plant showed that when keeping the reaction temperatures of pyrolyzer and gasifier respectively at about 700 °C and 850 °C, the heating value of fuel gas can reach 1200 kcal/Nm(3), and the tar content in the produced fuel gas was about 0.4 g/Nm(3). The results from this pilot industrial demonstration plant fully verified the feasibility and technical features of the proposed FB two-stage gasification process.

[Traumatic dislocation of superior tibiofibular joint].

OBJECTIVE: To explore the characteristics, diagnosis and treatment on traumatic dislocation. METHODS: From April 2000 to August 2010, 12 patients with acute traumatic dislocation of superior tibiofibular joint were treated including 10 males and 2 females with an average age of 30.6 years old ranging from 18 to 60 years. According to Ogden classification, 8 cases were the anterolateral dislocation, 2 were posterior-medial dislocation, and 2 were upward dislocation. All patients had swelling in lateral-inferior of knee, fibular head prominent, fibular head pain, floating feeling in head of fibula. One case was treated by conservative treatment, and the remaining 11 cases by surgical treatment. RESULTS: All patients were followed-up for 10 months to 3 years (means 18 months). Evaluation by Lysholm scoring,the total scores were 95.08 +/- 2.02, involving limbing 4.92 +/- 0.28, support 4.92 +/- 0.28, interlocking 15.00 +/- 0.00, instability 24.58 +/- 0.79, pain 22.50 +/- 1.24, swell 8.50 +/- 0.90, climbing stairs 9.75 +/- 0.62, squatting 4.92 +/- 0.28; 11 cases achieved excellent results and 1 good. Nerve functional recovered. X-ray was no longer dislocation. CONCLUSION: The diagnosis of traumatic dislocation is easy misseddiagnosis, surgery is the main treatment method, the prognosis is good.

[Coracoclavicular ligament reconstruction using autologous double-strand palmaris longus tendon and artificial ligament for the treatment of acromioclavicular joint dislocation].

OBJECTIVE: To investigate clinical effects of coracohumeral ligament reconstruction with autologous double-strand of long palmaris longus tendon and artificial ligament for the treatment of acromioclavicular joint dislocation. METHODS: From April 2006 to June 2009, 31 patients with acromioclavicular joint dislocation were treated with coracohumeral ligament reconstruction using autologous double-strand palmaris longus tendon and artificial ligament. There were 18 males and 13 females, ranging in age from 18 to 60 years, with an average of 35 years. Twenty-six patients were acute trauma and other 5 patients were chronic trauma. Preoperative symptoms included different degrees of pain, restricted movement, and instability of acromioclaviecular joint. The X-ray showed acromioclavicular joint dislocation. RESULTS: The patients had good incision union without vascular and nerve injuries. All the patients were followed up, and the average duration was 23 months. The JOA scores decreased from preoperative (38.8 +/- 1.5) to (73.2 +/- 1.1) at 1 month after operation,and (93.5 +/- 0.8)at the last follow-up. Twenty-eight patients got an excellent result, 2 good and 1 fair. CONCLUSION: The reconstruction of coracohumeral ligament using autologous double-strand palmaris longus tendon and artificial ligament is an effective method for the treatment of acromioclavicular joint dislocation.